Benzinga | Nov 11, 2021 08:39AM EST

PAVmed Subsidiary Lucid Diagnostics Launches Next Phase of Lucid Test Centers

rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer

Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (NASDAQ:PAVM, PAVMZ))))) ("PAVmed"), today announced it has launched Lucid Test Centers in three new metropolitan areas--Denver, Salt Lake City, and Las Vegas. Patients in these cities with chronic heartburn, also known as gastroesophageal reflux disease ("GERD"), who are referred by their primary care physician (PCP) or who self-refer can now undergo a rapid, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer. The test centers are staffed with Lucid-employed clinical personnel who use Lucid's EsoCheck(r) Cell Collection Device ("EsoCheck") to collect surface esophageal cells which are sent for Lucid's EsoGuard(r) DNA Esophageal Test ("EsoGuard"). Lucid believes EsoGuard and EsoCheck constitute the first and only commercially available test capable of serving as a widespread screening tool to prevent esophageal cancer deaths, through the early detection of esophageal precancer in at-risk GERD patients.